Newly presented data from KINECT-PRO, a phase 4 post-marketing study, showed that treatment with valbenazine (Ingrezza; Neurocrine Biosciences), an FDA-approved VMAT2 inhibitor, led to positive, real-world changes in physical, social, and emotional o... [3644 chars].. reed more
